Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Raphaël Vlavonou"'
Autor:
Vincent Pichette, Olivier Barrière, Pierre-Olivier Tremblay, Raphaël Vlavonou, Mario Tanguay, Eric Shink, Richard Larouche, Marc M. Perreault
Publikováno v:
The Journal of Clinical Pharmacology. 54:584-592
The pharmacokinetics of baclofen is well delineated in subjects with normal kidney function (KF); however, pharmacokinetics data in patients with chronic kidney disease (CKD) are not and dosage recommendations remain empirical. The effects of CKD on
Autor:
Raphaël, Vlavonou, Marc M, Perreault, Olivier, Barrière, Eric, Shink, Pierre-Olivier, Tremblay, Richard, Larouche, Vincent, Pichette, Mario, Tanguay
Publikováno v:
Journal of clinical pharmacology. 54(5)
The pharmacokinetics of baclofen is well delineated in subjects with normal kidney function (KF); however, pharmacokinetics data in patients with chronic kidney disease (CKD) are not and dosage recommendations remain empirical. The effects of CKD on
Autor:
Raphaël Vlavonou, Tomáš Hauser, Fethi Trabelsi, Lucie Navrátilová, Mario Tanguay, Charlotte Dubé, Aleš Bartůnek
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics.
Background Rosuvastatin, a synthetic lipid-lowering agent acts selectively by competitive inhibition of 3-hydroxy- 3-methylglutaryl-coenzyme A. It is indicated as an adjunct to diet in patients with hypercholesterolemia and mixed dyslipidemia. Object